tbuckley/cabot-search huggingface dataset:
HOXB13 is an estrogen receptor responsive gene preferentially methylated in ER-positive breast cancer
Authors: Mathew J. Socha, Neveen Said, Joseph Kwang, Jeffrey R. Lee, Daron G. Ferris, Samuel C. Mok, Kouros Motamed
Journal: Cancer Research (2006)

1598  SPARC (secreted protein acidic and rich in cysteine), also known as Osteonectin/Basement Membrane (BM)-40, is a multifunctional matricellular glycoprotein with established roles in regulation of development, angiogenesis, tissue remodeling and repair, as well as a contextual role in tumor growth and metastasis. We have previously shown repression of tumor-derived SPARC expression to be essential for ovarian carcinogenesis and inversely correlated with the metastatic stage of the disease. Therefore, we hypothesized that the loss of SPARC expression in ovarian cancer is due to aberrant methylation of the SPARC gene. Immunoblotting and immunohistochemical scoring methods were used to determine the expression levels of SPARC in 8/9 human ovarian cancer cell lines and 18/20 tumor tissues from patients at various stages of ovarian carcinoma. Primary and immortalized human ovarian surface epithelial (HOSE) cells and tissues from normal patients and patients with benign tumors were used as controls. The extent of methylation of CpG islands in the SPARC promoter of cell lines or laser-captured microdissected (LCM) tumor cells from tissue samples of patients were quantified by methylation-specific PCR (MSP) methodology. Our results revealed that strong SPARC expression levels in primary and immortalized HOSE cells and ovarian tumor cells of normal and benign patients were correlated with undetectable levels of promoter methylation. Conversely, aberrant methylation of SPARC promoter in ovarian carcinoma cell lines and tumor cells of patients with borderline and invasive grades strongly correlated with low or absent levels of SPARC expression. Moreover, repression of SPARC expression by methylation was shown to be reversible by treatment of ovarian cancer cell lines with the demethylating agent 5-aza-2-deoxycytidine. Collectively, our data suggest that the abnormal epigenetic silencing of SPARC expression associated with the progression of ovarian cancer is a relatively early event due to hypermethylation of the SPARC gene. This work was supported in part by National Institutes of Health Grant 1K01 CA89689 and The Georgia Cancer Coalition Grant GCC00023 (to K.M.).
Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis
Authors: Rute Nunes, Sarah Bogas, Maria João Faria, Hugo Gonçalves, Marlene Lúcio, Teresa Viseu, Bruno Sarmento, José das Neves
Journal: Journal of Controlled Release (2021)
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Authors: Jaume Capdevila, Nicola Fazio, Carlos Lopez, Alexandre Teulé, Juan W. Valle, Salvatore Tafuto, Ana Custodio, Nicholas Reed, Markus Raderer, Enrique Grande, Rocio Garcia-Carbonero, Paula Jimenez-Fonseca, Jorge Hernando, Alberto Bongiovanni, Francesca Spada, Vicente Alonso, Lorenzo Antonuzzo, Andrea Spallanzani, Alfredo Berruti, Adelaida La Casta, Isabel Sevilla, Patrizia Kump, Dario Giuffrida, Xavier Merino, Lorena Trejo, Pablo Gajate, Ignacio Matos, Angela Lamarca, Toni Ibrahim
Journal: Journal of Clinical Oncology (2021)

PURPOSE Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression to targeted agents (TAs). We investigated the efficacy and safety of lenvatinib in patients with previously treated advanced GEP-NETs. PATIENTS AND METHODS This was a multicenter, single-arm, open-label, phase II trial with two parallel cohorts (ClinicalTrials.gov identifier: NCT02678780 ) involving 21 institutions in 4 European countries. Eligible patients had histologically confirmed advanced grade 1-2 pancreatic (panNET) or GI (GI-NET) NETs with documented tumor progression after treatment with a TA (panNET) or somatostatin analogs (GI-NET). Patients were treated with lenvatinib 24 mg once daily until disease progression or treatment intolerance. The primary end point was overall response rate by central radiology review. Secondary end points included progression-free survival, overall survival, duration of response, and safety. RESULTS Between September 2015 and March 2017, a total of 111 patients were enrolled, with 55 (panNET) and 56 (GI-NET) patients in each cohort. The median follow-up was 23 months. The overall response rate was 29.9% (95% CI, 21.6 to 39.6): 44.2% (panNET) and 16.4% (GI-NET). The median (range) duration of response was 19.9 (8.4-30.8) and 33.9 (10.6-38.3) months in the panNET and GI-NET groups, respectively. The median progression-free survival was 15.7 months (95% CI, 14.1 to 19.5). The most common adverse events were fatigue, hypertension, and diarrhea; 93.7% of patients required dose reductions or interruptions. CONCLUSION We report the highest centrally confirmed response reported to date with a multikinase inhibitor in advanced GEP-NETs, with a particularly strong response in the panNET cohort. This study provides novel evidence for the efficacy of lenvatinib in patients with disease progression following treatment with other TAs, suggesting the potential value of lenvatinib in the treatment of advanced GEP-NETs.
Cytokine-skewed Tfh cells: functional consequences for B cell help
Authors: Adesola C. Olatunde, J. Scott Hale, Tracey J. Lamb
Journal: Trends in Immunology (2021)

CD4+ follicular helper T (Tfh) cells play a vital role in providing help for B cells undergoing selection and differentiation into activated antibody-secreting cells in mammalian germinal centers (GCs). Increasing evidence suggests that Tfh cells are a heterogeneous population that generates cytokine-skewed immune responses - a reflection of the microenvironment during differentiation. This has important ramifications for Tfh-mediated B cell help. Because Tfh subsets can have opposing effects on GC B cell responses, we discuss current findings regarding the differentiation and functions of cytokine-skewed Tfh cells in modulating GC B cell differentiation. Antibodies are important weapons against infectious diseases but can also be pathogenic mediators in some autoimmune conditions. Since cytokine-skewed Tfh cells can influence the magnitude and quality of the humoral response, we address the roles of cytokine-skewed Tfh cells in disease.
SALINE-INDUCED PD/PA RATIO CAN EASILY AND ACCURATELY EVALUATE FUNCTIONAL SIGNIFICANCE OF CORONARY STENOSIS
Authors: Ryo Takano, Yoshiharu Fujimori, Daisuke Yokota, Naoki Koike, Tomoko Baba, Wataru Takeuchi, Kyohei Yamazaki, Kazuto Kurihara, Satoshi Hashimoto, Yasushi Yamanaka, Yuya Terasawa, Tadamasa Wakabayashi, taku imai
Journal: Journal of the American College of Cardiology (2021)
EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19
Authors: Amna Zafar, Jay Khambhati, Zsofia Drobni, Carlos Gongora, Nora K. Horick, Andrea Foulkes, Naomi J. Serling-Boyd, Nina Lin, Ann E. Woolley, Sarah Hartmann, Hannah K. Gilman, Ana Fernandes, Liam Harvey, Chana Sacks, Michael Dougan, Crystal M. North, Arthur Y. Kim, Sara Schoenfeld, Pritha Sen, Eric Meyerowitz, James L. Januzzi, Matthew J. Frigault, Michael K. Mansour, John H. Stone, Tomas Neilan
Journal: Journal of the American College of Cardiology (2021)
Administration of fusion cytokines induces tumor regression and systemic antitumor immunity
Authors: Jinyu Zhang, Xuan Zhao
Journal: MedComm (2021)

It is difficult to improve the curative effects of cancer immunotherapy on solid tumors. Cytokines, as powerful immune regulators, show potential in activating host antitumor immunity. We have previously found that the administration of certain cytokine combinations induces complete tumor clearance. Here, we constructed cognate fusion cytokines and evaluated their antitumor effects in various mouse tumor models. The in situ induction of the expression of the fusion cytokine IL12IL2GMCSF caused tumor eradication, including that of the tumors at advanced stages. An immune memory against unrelated syngeneic tumors was also elicited. Furthermore, flow cytometry analysis revealed that tumor-infiltrating CD3+ cells were greatly increased in the treated tumors and were accompanied by an elevation of CD8+/CD4+ ratios. This fusion protein exhibited superior immune activating capability compared to that of cytokine mixtures, in the experiments done in vitro. We also induced tumor regression in various immunocompetent tumor models via intratumoral injection. To improve its translational potential for clinical application, a systemically-administered immunocytokine, IL12IL2DiaNFGMCSF, was constructed by inserting a tumor-targeting diabody in the fusion protein. This protein also displayed good immune stimulating activities in vitro. Intravenous infusion of IL12IL2DiaNFGMCSF induced tumor-infiltrating immune cell alterations like IL12IL2GMCSF, with moderate serum IFNγ increment. Therapeutic effects were observed in the various tumor models after systemic administration of IL12IL2DiaNFGMCSF, but with slight toxicity. These results show the feasibility of developing a versatile cancer immunotherapy.
Huff and puff of exercise for airway clearance in cystic fibrosis: how clear is the evidence?
Authors: Tiffany Dwyer
Journal: Thorax (2021)

Cystic fibrosis (CF) lung disease is characterised by reduced mucus clearance, resulting in retention of thick mucus, creating a nidus for chronic infection and progressive lung damage. A cornerstone of the medical management of CF lung disease is daily airway clearance therapy (ACT), tailored to the individual, such as active cycle of breathing technique (ACBT), autogenic drainage, positive expiratory pressure (PEP) and oscillating PEP devices, postural drainage, percussion and high-frequency chest wall oscillations.1 There is widespread agreement among people with CF and healthcare professionals that exercise may also improve airway clearance2 and many people with CF already use exercise as a substitute for ACT.3 Whether exercise is a satisfactory substitute for traditional ACTs in people with CF has been identified as a top 10 research priority,4 yet none of the many systematic reviews on the various ACTs have answered this question, as in the five systematic reviews5 only one study was eligible for inclusion, and the systematic review on exercise training did not specifically address airway clearance.6 People with CF are encouraged to regularly exercise,1 due to the known benefits on exercise capacity and potential improvements in lung function and quality of life.6 If exercise could adequately replace traditional ACTs for people with CF, it may also reduce …
Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib
Authors: Omid Zahedi Niaki, Erin Penn, Deborah A. Scott, Gabriela Cobos, Ruth Ann Vleugels, Michael E. Weinblatt
Journal: JAMA Dermatology (2021)

This case report describes a woman in her 50s with arthralgias and erythematous nonpruritic papules and papulonodules on the face, arms, and trunk and a medical history of hypertension, coronary artery disease, and a remote history of breast and ovarian carcinoma in situ.
Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling
Authors: Gwenneg Kerdivel, Virginie Chesnais, Etienne Becht, Andrea Toma, Nicolas Cagnard, Florent Dumont, Alice Rousseau, Pierre Fenaux, Sylvie Chevret, Nicolas Chapuis, Valentina Boeva, Wolf-Herman Fridman, Olivier Kosmider, Michaela Fontenay
Journal: Blood (2017)
Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
Authors: Claire Amaris Hobson, Aurélie Cointe, Hervé Jacquier, Alaksh Choudhury, Mélanie Magnan, Céline Courroux, Olivier Tenaillon, Stéphane Bonacorsi, André Birgy
Journal: Clinical Microbiology and Infection (2021)

Ceftazidime-avibactam (CZA) and cefiderocol are recently commercialized molecules active against highly drug-resistant bacteria, including carbapenem-resistant members of the Enterobacteriaceae. Mutants resistant to CZA have been described, notably in Klebsiella pneumoniae carbapenemase (KPC) producers. Considering the structural similarities between ceftazidime and cefiderocol, we hypothesized that resistance to CZA in KPC-producing members of the Enterobacterales may lead to cross-resistance to cefiderocol.CZA-resistant mutants from three clinical isolates of the Enterobacterales carrying either blaKPC-2 or blaKPC-3 were selected in vitro. Mutants with increased MIC to CZA compared to the ancestral allele were cloned in a pBR322 plasmid and expressed in Escherichia coli TOP10. We evaluated the impact of these mutations on cefiderocol MICs and minimal bactericidal concentrations (MBCs), and we assessed the impact of bacterial inoculum size on cefiderocol MICs.We used 37 KPC mutants with increased CZA MICs. Of these, six have been described previously in clinical isolates. Compared to the wild-type alleles, increases in the cefiderocol MICs of 4- to 32-fold were observed for 75.6% of tested mutants (28/37), MICs reaching up to 4 mg/L in E. coli TOP10 for KPC-31 (D179Y-H274Y mutations). MBCs and MICs of cefiderocol were similar, confirming the bactericidal activity of this drug. Finally, when using higher inocula (107 CFU/mL), a large increase in cefiderocol MIC was observed, and all isolates were categorized as resistant.We observed that most of the CZA-resistant KPC variants have a possible impact on cefiderocol by increasing the cefiderocol MICs. In addition, cefiderocol is greatly impacted by the inoculum effect, suggesting that precautions should be taken when treating infections with a suspected high inoculum.
Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: Results of a Double-Blind Randomized Clinical Trial (FORWARD) (NCT00597220)
Authors: Macchia Alejandro, Grancelli Hugo, Varini Sergio, Nul Daniel, Ferrante Daniel, Mariani Javier, Laffaye Nicolas, Badra Raul, Figal Julio, Ramos Silvina, Tognonl Gianni, Doval Hernan
Journal: Circulation (2012)
A Programmed Cell‐Mimicking Nanoparticle Driven by Potato Alkaloid for Targeted Cancer Chemoimmunotherapy
Authors: Jie Li, Wei Tang, Yi Yang, Qing Shen, Yang Yu, Xiaoyou Wang, Yu Fu, Chong Li
Journal: Advanced Healthcare Materials (2021)

Abstract Membrane camouflaged‐nanoparticles (CM‐NPs) have been exploited to inherit desired functionalities from source cells. Despite those advantages, membrane cloak may play a “double‐edged sword” role in tumor‐targeting therapy, as the intact membrane coating may hinder function‐exertion of loaded drugs after reaching predetermined site. Therefore, further optimization of CM‐NPs is still needed to enhance their delivery efficiency. Herein, natural product, Solamargine (SM), a cholesterol‐affiliative amphiphilic potato alkaloid is first applied as core component of “inner core,” to design a cell‐mimicking “core–shell” nanoparticle (RBC‐SLip) with acid‐responsive off‐coating properties for tumor‐targeted therapy. Owing to red blood cell membrane (RBCm)‐derived outer coating, it circulates stably in physiological conditions. While it would undergo an off‐coating morphological change in response to acid stimuli in tumor microenvironment (TME), afterwards, the resulting off‐coating liposome (SLip) shows active tumor‐targeting and endosomal escape abilities, thus contributing to superior antitumor efficacy. In addition, SM also possesses natural TME‐modulating ability; therefore, RBC‐SLip can synergize with the PD1/PD‐L1 blockade immunotherapy when encapsulated with PTX to achieve enhanced chemoimmunotherapy. The off‐coating strategy developed by natural products SM, provide a brand‐new perspective to optimize CM‐NPs, and it also embodies application value of “unification of medicines and excipients” of natural products.
Sharing health data for immigration control affects marginalised communities
Authors: Lauren Z Waterman, Mishka Pillay, Cornelius Katona
Journal: BMJ (2021)

Stokel-Walker raises an important concern that relaxation of data sharing restrictions during the covid-19 pandemic might continue after the pandemic has ended.1 There was mixed opinion about the sharing of some data between healthcare providers and authorities at the height of the crisis, such as to enable police to enforce self-isolation to reduce the spread of covid-19.2 It is essential, however, that further …
VOLUMES AND OUTCOMES OF TRICUSPID VALVE SURGERY WITH CONCOMITANT MITRAL VALVE SURGERY
Authors: Hassaan Arshad, Abdul Mannan Khan Minhas, Safi Khan, Khurram Nasir, Sara Ayaz Butt, Moritz Wyler von Ballmoos, Neal Kleiman, Michael Reardon, Sachin Goel
Journal: Journal of the American College of Cardiology (2021)
CONTRARY TO CURRENT POPULATION HEALTH MANAGEMENT TRENDS: HOW A HIGH-RISK TELE-HOSPITAL MODEL CAN IMPROVE CARE QUALITY AND COST IN TOP 5% HIGH-RISK/COST POPULATION
Authors: Michael Shen, Kaelin DeMuth, Irene Kouz, Julio Llanga, Kareem Osman, Sheree Baron, Yixiang Liu, Ioana Dumitru, Ahmed Osman
Journal: Journal of the American College of Cardiology (2021)
Observations of SARS-CoV-2 variant of concern B.1.1.7 at the UK's largest hospital trust
Authors: Mark I. Garvey, Claire McMurray, Anna L Casey, Liz Ratcliffe, Joanne Stockton, Martyn A C Wilkinson, Elisabeth Holden, Husam Osman, Nick J Loman
Journal: Journal of Infection (2021)
Ptpn2 and KLRG1 regulate the generation and function of tissue-resident memory CD8+ T cells in skin
Authors: Katharina Hochheiser, Florian Wiede, Teagan Wagner, David Freestone, Matthias H. Enders, Moshe Olshansky, Brendan Russ, Simone Nüssing, Emma Bawden, Asolina Braun, Annabell Bachem, Elise Gressier, Robyn McConville, Simone L. Park, Claerwen M. Jones, Gayle M. Davey, David E. Gyorki, David Tscharke, Ian A. Parish, Stephen Turner, Marco J. Herold, Tony Tiganis, Sammy Bedoui, Thomas Gebhardt
Journal: The Journal of Experimental Medicine (2021)

Tissue-resident memory T cells (TRM cells) are key elements of tissue immunity. Here, we investigated the role of the regulator of T cell receptor and cytokine signaling, Ptpn2, in the formation and function of TRM cells in skin. Ptpn2-deficient CD8+ T cells displayed a marked defect in generating CD69+ CD103+ TRM cells in response to herpes simplex virus type 1 (HSV-1) skin infection. This was accompanied by a reduction in the proportion of KLRG1− memory precursor cells and a transcriptional bias toward terminal differentiation. Of note, forced expression of KLRG1 was sufficient to impede TRM cell formation. Normalizing memory precursor frequencies by transferring equal numbers of KLRG1− cells restored TRM generation, demonstrating that Ptpn2 impacted skin seeding with precursors rather than downstream TRM cell differentiation. Importantly, Ptpn2-deficient TRM cells augmented skin autoimmunity but also afforded superior protection from HSV-1 infection. Our results emphasize that KLRG1 repression is required for optimal TRM cell formation in skin and reveal an important role of Ptpn2 in regulating TRM cell functionality.
TRANSCATHETER AORTICVALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN AORTIC STENOSIS WITH BICUSPID AORTIC VALVE AND CHRONIC CORONARY ARTERY DISEASE NATIONWIDE INPATIENT ANALYSIS 2017
Authors: Yaser Khalid, Neethi Dasu, Kirti Dasu, Herman Suga
Journal: Journal of the American College of Cardiology (2021)
PTU-020 High levels of “presumed polyp miss rate” at 1 and 3 years following index screening colonoscopy: no room for complacency
Authors: R Rameshshanker, F Purchiaroni, W Ana, S Thomas-Gibson, A Rajendran, I Stasinos, Z Tsiamoulos, BP Saunders
Journal: Gut (2017)

Introduction  Despite improvements in colonoscopy training and technology, it remains as an imperfect tool and the adenoma miss rates (AMR) vary between 6%–27%. Aim is to determine the presumed AMR and sessile serrated adenomas/polyps (SSA/Ps) miss rate after a complete screening colonoscopy.  Method  It is a single centre prospective observational study over 12 months from July 2015. Patients who underwent 1 and 3 year screening surveillance colonoscopy performed by accredited screening colonoscopists were included. Polyp characteristics and procedural data were prospectively collected. Polyp histology and epidemiology data were retrieved from our endoscopy database. A polyp was considered as “missed” at the index colonoscopy if at 1 year surveillance or at 3 years if >5 mm, and not a recurrence.  Results  241 patients underwent a surveillance colonoscopy (male: female 2:1, median age 65 years). 90/241 (37.3%) patients had a one year surveillance colonoscopy. There was no significant difference in the quality of bowel preparation and caecal intubation rate between index and surveillance procedures. Total number of polyps detected during index and surveillance colonoscopies were 815 and 469 respectively. The presumed miss rate of polyps, adenomas, SSA/Ps and advanced adenomas were 37.8% (469/1241),22.1% (176/798),41.7% (20/48) and 15.2% (36/236) respectively. More adenomas were missed in the proximal colon (Image 1- missed adenoma and SSA/P in each segment) when compared to distal colon (26.64% vs 18.04%, p=0.01). Adenoma miss rates per size were 23.7%,27.1% and 8.3% for diminutive,small and adenoma >1 cm respectively.Higher number of polyps (>3) detected during index colonoscopy independently correlated with high miss rates (84.3% vs 72%, p=0.04).  Conclusion  Our study highlights that there is a significant miss rate for adenomas and SSA/Ps even after careful index colonoscopy. Miss rate was higher when multiple polyps are seen at the index examination. This finding appears to justify the current BSG guidelines for one year colonoscopy when multiple polyps are seen. The presumed polyp miss rate at 1 and 3 years may be justified as a new quality metric.  Disclosure of Interest  None Declared
Abstract 12012: Lower Circulating Levels of Cyclic Guanosine Monophosphate Are Associated With Greater Concentric Left Ventricular Remodeling in the Multi-Ethnic Study of Atherosclerosis
Authors: Vinita Subramanya, Wendy Ying, Di Zhao, Dhananjay Vaidya, Chiadi E Ndumele, Joao A Lima, Pamela Ouyang, Ron C Hoogeveen, Sanjiv J Shah, Susan R Heckbert, David A Kass, Wendy S Post, Erin D Michos
Journal: Circulation (2018)

Introduction: Increased left ventricular (LV) mass and concentric remodeling (i.e. increased Mass (M): Volume (V) ratio) are important risk markers of heart failure (HF) with preserved ejection fra...
Abstract 12324: Machine Learning-based Prediction of Cardiovascular Death in Patients With Hypertrophic Cardiomyopathy
Authors: Stephanie M Kochav, Yoshihiko Raita, Michael A Fifer, Hiroo Takayama, Jonathan Ginns, Mathew S Maurer, Muredach P Reilly, Kohei Hasegawa, Yuichi J Shimada
Journal: Circulation (2019)

Introduction: Hypertrophic cardiomyopathy (HCM) can lead to cardiovascular death (CVD) - e.g., sudden cardiac death with or without successful resuscitation, death due to heart failure, and heart t...
ASPIRIN REDUCED THE RISK OF DEATH IN PATIENTS WITH INFECTIVE ENDOCARDITIS
Authors: Hang Long Li, Si-Yeung Yu, Pui-Fai Wong, Shuk-Yin Yu, Yi-Kei Tse, Lok-Yee Lam, Calvin Leung, Kwan-Yu Li, Qingwen Ren, Meizhen Wu, Kai-Hang Yiu
Journal: Journal of the American College of Cardiology (2021)
CARDIAC INVOLVEMENT IN SARCOIDOSIS: A POOR PROGNOSTIC MARKER
Authors: Maria Vega Brizneda, Erika Hutt, Jose Aguilera, Tom Kai Ming Wang, Ziad Taimeh, Daniel Culver, Ayman Hussein, Thomas Callahan, Oussama Wazni, Wael Jaber, Paul Cremer, Manuel Ribeiro, Christine Jellis
Journal: Journal of the American College of Cardiology (2021)
EXERCISE-INDUCED VENTRICULAR ECTOPY AND FUTURE CARDIOVASCULAR DEATH IN ASYMPTOMATIC INDIVIDUALS: A 20-YEAR FOLLOW-UP OF THE LIPID RESEARCH CLINICS PREVALENCE STUDY
Authors: Charbel Gharios, Marwan M. Refaat, Farah Abdulhai, Roger Blumenthal, Miran A. Jaffa, Samia Mora
Journal: Journal of the American College of Cardiology (2021)